Business Description
Pharming Group
NAICS : 325414
SIC : 2836
ISIN : NL0010391025
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.21 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.81 | |||||
Debt-to-EBITDA | 13.43 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.3 | |||||
Beneish M-Score | -2.59 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | -44.4 | |||||
3-Year Book Growth Rate | 8.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 18.48 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 40.55 | |||||
9-Day RSI | 41.1 | |||||
14-Day RSI | 39.71 | |||||
6-1 Month Momentum % | -20.42 | |||||
12-1 Month Momentum % | -23.6 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.43 | |||||
Quick Ratio | 1.16 | |||||
Cash Ratio | 0.97 | |||||
Days Inventory | 661.73 | |||||
Days Sales Outstanding | 51.19 | |||||
Days Payable | 643.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.7 | |||||
Shareholder Yield % | -1.18 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 88.57 | |||||
Operating Margin % | -9.57 | |||||
Net Margin % | -4.13 | |||||
FCF Margin % | -1.35 | |||||
ROE % | -5.14 | |||||
ROA % | -2.43 | |||||
ROIC % | -11.12 | |||||
ROC (Joel Greenblatt) % | -11.11 | |||||
ROCE % | -2.06 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.3 | |||||
PB Ratio | 2.67 | |||||
Price-to-Tangible-Book | 3.95 | |||||
EV-to-EBIT | -72.1 | |||||
EV-to-Forward-EBIT | 351.32 | |||||
EV-to-EBITDA | 41.31 | |||||
EV-to-Forward-EBITDA | 67.92 | |||||
EV-to-Revenue | 1.98 | |||||
EV-to-Forward-Revenue | 1.72 | |||||
EV-to-FCF | -146.81 | |||||
Price-to-Projected-FCF | 1.21 | |||||
Price-to-Median-PS-Value | 0.48 | |||||
Price-to-Net-Current-Asset-Value | 9.38 | |||||
Earnings Yield (Greenblatt) % | -1.39 | |||||
FCF Yield % | -0.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Pharming Group Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 238.746 | ||
EPS (TTM) (€) | -0.014 | ||
Beta | -0.16 | ||
Volatility % | 27.88 | ||
14-Day RSI | 39.71 | ||
14-Day ATR (€) | 0.023641 | ||
20-Day SMA (€) | 0.765975 | ||
12-1 Month Momentum % | -23.6 | ||
52-Week Range (€) | 0.722 - 1.313 | ||
Shares Outstanding (Mil) | 673.44 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Pharming Group Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Pharming Group Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Pharming Group Frequently Asked Questions
What is Pharming Group(XAMS:PHARM)'s stock price today?
When is next earnings date of Pharming Group(XAMS:PHARM)?
Does Pharming Group(XAMS:PHARM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |